NCT03514784View on ClinicalTrials.gov

Combination Probiotic: BB-12 With LGG (Different Doses) in Treating Children With Autism Spectrum Disorder

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Autism Spectrum DisorderGastrointestinal Symptoms
Interventions
DRUG

BB-12 with LGG (Higher Dose)

BB-12 with LGG - Higher Dose (10 billion CFUs)

DRUG

Placebo

Maltodextrin

DRUG

BB-12 with LGG (Lower Dose)

BB-12 with LGG - Lower Dose (1 billion CFUs)

Trial Locations (1)

77030

RECRUITING

UTHealth, Houston

All Listed Sponsors
collaborator

Texas Higher Education Coordinating Board

OTHER_GOV

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

The University of Texas Health Science Center, Houston

OTHER